Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngene International's ROE % for the quarter that ended in Mar. 2026 was 12.23%. Syngene International's PB Ratio for the quarter that ended in Mar. 2026 was 3.24.
Syngene International's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.77%.
Syngene International ROE % Adjusted to Book Value Related Terms
Syngene International ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Syngene International's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngene International ROE % Adjusted to Book Value Chart
NSE:SYNGENE vs TMO, DHR, IDXX: ROE % Adjusted to Book Value Comparison
For the Diagnostics & Research subindustry, Syngene International's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Syngene International's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 3.77% mean?
Syngene International (NSE:SYNGENE) has a ROE % Adjusted to Book Value of 3.77% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Syngene International and its competitors.
Is Syngene International's ROE % Adjusted to Book Value too high?
Syngene International's current ROE % Adjusted to Book Value is 3.77%. Overall, Syngene International has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's ROE % Adjusted to Book Value compare to TMO and DHR?
Syngene International's ROE % Adjusted to Book Value of 3.77% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Syngene International and its competitors. Syngene International's current ROE % Adjusted to Book Value is 3.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹770.19, compared to a current price of ₹417.60 — trading 45.8% below its estimated fair value. The current ROE % Adjusted to Book Value is 3.77%. Syngene International's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current ROE % Adjusted to Book Value is 3.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹417.60 is trading 45.8% below its estimated GF Value™ of ₹770.19.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
ROE % Adjusted to Book Value: 3.77%
GF Value™: ₹770.19 vs. price of ₹417.60 (45.8% below fair value)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
79GF Score
Get the complete analysis for NSE:SYNGENE
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
